在这项研究中，我们调查了慢性髓系白血病患者在伊马替尼治疗期间的肾功能和贫血状况。我们在印度新德里Rajiv Gandhi癌症研究中心选取仅接受伊马替尼治疗12个月的慢性髓系白血病患者，并进行前瞻性分析。从2020年6月到2022年6月，我们对新诊断的慢性髓系白血病-慢性期患者的肾功能和贫血指标（包括估价肾小球滤过率和血红蛋白水平）进行了监测。我们使用SPSS软件的22版对数据进行了分析。我们一共监测了55名接受伊马替尼治疗12个月的慢性髓系白血病慢性期患者。平均估价肾小球滤过率显著下降（74±14至59±12mL/min/1.73m²，p<0.001），并伴随12个月后平均血红蛋白水平的下降（10.9±2.01至9.0±1.02，p<0.004）。经过1年伊马替尼治疗后，估价肾小球滤过率的下降与血红蛋白水平呈负相关（相关系数=0.892，R2=0.7976，p<0.05）。我们建议密切监测慢性髓系白血病患者的肾功能和血红蛋白水平。

In this study, we investigate renal function and anaemia during imatinib treatment in patients with chronic myeloid leukaemia.The patients with chronic myeloid leukaemia with chronic phase who had been treated with only imatinib for 12 months at Rajiv Gandhi Cancer Institute and Research Centre (New Delhi, India) were enrolled and prospectively analysed. The chronic renal impairment parameters, including estimated glomerular filtration rate and haemoglobin levels for anaemia from June 2020 to June 2022, were monitored in newly diagnosed in patients with chronic myeloid leukaemia-chronic phase. The data were analysed by SPSS software version 22.In total 55 patients with chronic myeloid leukaemia chronic phase who had been on imatinib for 12 months were monitored. The mean estimated glomerular filtration rate was significantly decreased (74 ± 14 to 59 ± 12 mL/min/1.73m2, p < 0.001) with a decrease in mean haemoglobin levels after 12 months (10.9 ± 2.01 to 9.0 ± 1.02, p < 0.004). The decreased estimated glomerular filtration rate was negatively correlated with haemoglobin levels after 1 year of imatinib administration (correlation coefficient = 0.892, R2 = 0.7976, p < 0.05).We recommended close monitoring of renal function and haemoglobin levels in patients with chronic myeloid leukaemia patients.